GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xintela AB (OSTO:XINT) » Definitions » Policy Acquisition Expense

Xintela AB (OSTO:XINT) Policy Acquisition Expense


View and export this data going back to 2016. Start your Free Trial

What is Xintela AB Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Xintela AB (OSTO:XINT) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Medicon Village, Lund, SWE, 22381
Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based therapies for Glioblastoma and Tripple-negative breast cancer. XSTEM is also evaluated for the treatment of the severe and deadly lung complication ARDS, which may affect covid-19 patients.